SAN DIEGO--(BUSINESS WIRE)--Mentor Capital, Inc.'s (Pink Sheets:MNTR) Cancer Immunotherapy Index, created July 10, 2009, closed out the year with a 41% gain after just 25 weeks of measurement. The 85% annualized rate of gain of the Cancer Immunotherapy Index was greater than the also strong 53% annualized gain of the average of representative biotech indexes from NASDAQ, S&P and the NYSE during the same period.
